We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Next-Gen Products Driving Global POC Molecular Diagnostics Market

By LabMedica International staff writers
Posted on 31 Dec 2018
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.

These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

The growing number of M&As and collaborations is acting as a key growth driver of the global POC molecular diagnostics market. More...
Large companies have been increasingly acquiring and collaborating with specialized POC molecular diagnostic companies to expand their product portfolio. As a result, the parent companies have reduced their internal costs for product development, clinical study, and regulatory approvals.

The growing emphasis on technological advances will accelerate the growth of the global POC molecular diagnostics market. Advances in the field of information technology are providing ease of transmission by electronically recording and transferring the data captured. The shift from curative medicine to predictive, personalized, and preemptive medicine is also driving an increasing demand for POC molecular diagnostics. This shift, coupled with advances in the field of biosensors, smartphones, wearables, and lab-on-a-chip, is expected to improve the market. For instance, the lab-on-a-chip diagnostics system is formed based on the disposable, single-use, credit card sized, plastic cassette that hosts a microfluidic network for sample processing and analysis. Hence, several companies are adopting this advancement to broaden their product and service portfolios.

Based on application, the infectious diseases segment held the largest market share of more than 45% in 2018 and is expected to continue dominating the market during the forecast period. Geographically, the Americas led the global POC molecular diagnostics market in 2018 with a share of around 56%, followed by the EMEA and APAC. The Americas is expected to continue dominating the market during the forecast period.

Related Links:
Technavio Research


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.